SpyGlass Pharma Presents Compelling 3-Month Data from the First-In-Human Trial of Its Innovative Drug Delivery Platform for Chronic Eye Conditions

“We are pleased to share the 3-month results from our First-in-Human clinical trial. The SpyGlass drug delivery platform holds great promise for patients living with glaucoma and other chronic eye conditions,” said Malik Y. Kahook, MD, Co-Founder, President and Executive Chairman of the Board at SpyGlass Pharma, and Vice Chair of Translational Research and the Slater Family Endowed Chair in Ophthalmology at the Sue Anschutz-Rodgers Eye Center.

.